BioSenic S.A. (EBR: BIOS)
Belgium
· Delayed Price · Currency is EUR 0.0093
+0.0003 (3.33%)
Sep 3, 2024, 5:22 PM CET
BioSenic Company Description
BioSenic S.A., a biotech company, focuses on developing clinical assets.
Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis.
The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Contact Details
Address: Building H (box 24) Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 493 09 73 66 |
| Website | biosenic.com |
Stock Details
| Ticker Symbol | BIOS |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974280126 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Véronique Pomi-Schneiter | Deputy Chief Executive Officer and Executive Director |
| Prof. François Rieger | Chief Executive Officer and Chairman |
| Dr. Carole Nicco | Chief Scientific Officer and Chief Operating Officer |
| Alexia Rieger | Chief Investor Relation Officer |
| Dr. Lieven Huysse M.D. | Chief Medical Officer |